Electromed, Inc. ELMD

Healthcare SIC 3845 - Electromedical & Electrotherapeutic Apparatus NYSE

Electromed, Inc. ("we," "our," "us," "Electromed" or the "Company") develops, manufactures, markets and sells innovative products that provide airway clearance therapy, including the SmartVest® Airway Clearance System ("SmartVest System") to patients with compromised pulmonary function with a commitment to excellence and compassionate service. Our goal is to make High Frequency Chest Wall Oscillation ("HFCWO") treatments as effective, convenient, and comfortable as possible, so our patients can breathe easier and live better with improved respiratory function and fewer exacerbations.

We primarily employ a direct-to-patient and provider model, through which we obtain patient referrals from clinicians, manage insurance claims on behalf of our patients, and deliver the SmartVest System to patients, training them on proper use in their homes. This model allows us to directly approach patients and clinicians, whereby we disintermediate the traditional home medical equipment ("HME") channel and capture both the manufacturer and distributor margins. We also sell our products in the acute care setting for patients in a post-surgical or intensive care unit, or who were admitted for a lung infection brought on by compromised airway clearance. Electromed was incorporated in Minnesota in 1992. Our common stock is listed on the NYSE American under the ticker symbol "ELMD."

Last close 28.00 2026-09-04
Market cap $234.3M 2026-06-30 share count
52-week range 23.01 - 47.40

Valuation FY2026 figures against the last close

P/S3.2x
P/E21.5x
P/FCF27.8x
EV/EBITDA15.9x
Dividend yield
Diluted EPS1.30

Annual financial statements

Income statement

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue $73.8M$64.0M$54.7M$48.1M$41.7M$35.8M$32.5M$31.3M$28.3M$25.9M
Cost of revenue $15.8M$14.0M$13.0M$11.5M$10.2M$8.5M$7.3M$7.5M$6.5M$5.3M
Gross profit $57.9M$50.0M$41.7M$36.5M$31.4M$27.3M$25.2M$23.8M$21.8M$20.6M
R&D $1.3M$996.0K$656.0K$916.0K$1.4M$1.7M$1.1M$583.3K$251.4K$596.9K
SG&A $42.7M$39.3M$34.5M$31.6M$27.1M$22.4M$19.9M$20.4M$18.8M$16.4M
Total operating expenses $44.1M$40.3M$35.1M$32.5M$28.5M$24.2M$20.1M$21.0M$19.1M$17.0M
Operating income $13.9M$9.7M$6.6M$4.0M$3.0M$3.1M$5.1M$2.8M$2.7M$3.6M
Interest expense $455.0K$78.0K$25.0K$27.0K$121.0K$90.7K$19.9K$49.9K
Pre-tax income $14.4M$10.3M$7.0M$4.1M$3.0M$3.2M$5.2M$2.9M$2.7M$3.5M
Income tax $3.1M$2.7M$1.9M$920.0K$692.0K$805.0K$1.1M$940.0K$901.0K$1.3M
Net income $11.3M$7.5M$5.2M$3.2M$2.3M$2.4M$4.2M$2.0M$1.8M$2.2M
EPS, basic 1.370.890.600.370.270.280.500.240.220.27
EPS, diluted 1.300.850.580.360.260.270.470.230.210.26
Shares, diluted (wtd. avg.) $8.7M$8.9M$8.9M$8.7M$8.8M$8.9M$8.8M$8.6M$8.6M$8.5M

Balance sheet

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents $20.4M$15.3M$16.1M$7.4M$8.2M$11.9M$10.5M
Receivables $29.8M$24.7M$23.3M$24.1M$21.1M$17.0M$12.9M$12.8M$11.8M$9.9M
Inventory $3.7M$3.3M$3.7M$4.2M$3.2M$2.1M$3.1M$2.6M$2.5M$2.6M
Total current assets $57.4M$45.1M$44.2M$37.8M$34.5M$31.7M$28.0M$24.5M$23.3M$18.5M
Property, plant and equipment $5.2M$4.7M$5.2M$5.7M$4.6M$3.6M$3.8M$3.6M$3.1M$3.3M
Other intangibles $379.0K$371.0K$657.0K$605.0K$599.0K$663.0K$598.0K$581.0K$649.0K$721.0K
Total assets $66.3M$53.8M$52.2M$45.8M$41.4M$37.1M$33.2M$29.4M$27.4M$23.1M
Accounts payable $2.6M$2.7M$1.0M$1.4M$1.3M$685.0K$556.0K$586.6K$810.6K$663.4K
Short-term debt $33.0K$72.0K$30.3K$1.1M$50.7K
Total current liabilities $12.2M$10.5M$7.7M$8.1M$7.2M$4.6M$3.0M$3.7M$4.8M$2.9M
Long-term debt $1.1M
Total liabilities $12.3M$10.6M$7.7M$8.1M$7.2M$4.7M$3.0M$3.7M$4.7M$4.0M
Retained earnings $28.6M$21.2M$23.7M$18.8M$15.8M$14.9M$13.7M$9.5M$7.6M$5.0M
Total equity $54.0M$43.2M$44.5M$37.7M$34.2M$32.4M$30.2M$25.7M$22.6M$19.8M

Cash flow

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating cash flow $9.7M$11.4M$9.1M$1.3M-$686.0K$3.1M$4.2M$2.6M$2.4M$1.2M
Depreciation and amortisation $868.0K$1.0M$789.0K$550.0K$503.0K$477.0K$619.0K$804.6K$676.4K$636.7K
Stock-based compensation $2.7M$3.1M$1.7M$708.0K$976.0K$1.0M$902.0K$924.1K$862.7K$479.5K
Capital expenditure $1.3M$262.0K$287.0K$1.6M$1.4M$287.0K$844.0K$1.3M$526.2K$618.8K
Investing cash flow -$1.3M-$306.0K-$395.0K-$1.7M-$1.5M-$448.0K-$977.0K-$1.4M-$571.8K-$687.1K
Financing cash flow -$3.2M-$11.9M$36.0K-$380.0K-$1.5M-$1.2M-$548.0K-$851.2K$11.7K-$53.6K
Buybacks $3.9M$10.0M$275.0K$153.0K$1.4M$1.1M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-028914.

Others in SIC 3845

TickerCompanyMarket capP/ERevenue growth
MDT Medtronic plc $120.46B 25.2x 8.4%
LIVN LivaNova PLC $4.51B 10.7%
ITGR Integer Holdings Corp $4.30B 43.8x 8.0%
TMDX TransMedics Group, Inc. $3.12B 18.5x 37.1%
AXGN Axogen, Inc. $2.60B 20.2%
BLFS BIOLIFE SOLUTIONS INC $1.72B 28.9%
CNMD CONMED Corp $1.48B 32.7x 5.2%
CBLL Ceribell, Inc. $948.7M 36.1%